

## Special Issue

# Role of HSV-1 and Host Immune Response on Neurodegenerative Diseases

### Message from the Guest Editors

Most neurodegenerative diseases are multifactorial pathologies in which the combination of different factors plays a pivotal role. Chronic bacterial and viral infections are considered as risk factors for neurodegenerative conditions, although it is still controversial as to how they contribute to the development and progression of these devastating diseases. The possibility that HSV-1 could be involved in the pathogenesis of AD was originally hypothesized 40 years ago, and, in the last ten years, many studies have explored this possibility, focusing also on the role of HSV-1-specific host immune responses in this scenario. For this Special Issue, we invite contributions (original reports or reviews) that explore these areas of research, especially focusing on:

- Viral and host factors contributing to the outcome of HSV-1 infection and their association with neurodegenerative diseases;
- Molecular mechanisms involved in HSV-1 reactivation and their possible role in the onset of neurodegenerative diseases;
- Epidemiologic study on the association between HSV-1 infection and neurodegenerative diseases;
- Possible development of vaccines against HSV-1.

### Guest Editors

Dr. Simone Agostini

Laboratorio di Medicina Molecolare e Biotech, Institution of IRCCS  
Fondazione Don Carlo Gnocchi, 20162 Milan, Italy

Dr. Roberta Mancuso

IRCCS Fondazione Don Carlo Gnocchi, 20162 Milan, Italy

### Deadline for manuscript submissions

closed (15 November 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/56277](https://mdpi.com/si/56277)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).